602 related articles for article (PubMed ID: 23261355)
1. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
2. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.
Liao GD; Sellors JW; Sun HK; Zhang X; Bao YP; Jeronimo J; Chen W; Zhao FH; Song Y; Cao Z; Zhang SK; Xi MR; Qiao YL
Int J Cancer; 2014 Apr; 134(7):1715-24. PubMed ID: 24105727
[TBL] [Abstract][Full Text] [Related]
6. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
10. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
11. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
12. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study.
White C; Bakhiet S; Bates M; Keegan H; Pilkington L; Ruttle C; Sharp L; O' Toole S; Fitzpatrick M; Flannelly G; O' Leary JJ; Martin CM
Cytopathology; 2016 Aug; 27(4):269-76. PubMed ID: 26932360
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of p16-INK4A protein in women with negative or CIN1 histology result: a follow-up study.
Pacchiarotti A; Ferrari F; Bellardini P; Chini F; Collina G; Dalla Palma P; Ghiringhello B; Maccallini V; Musolino F; Negri G; Pisa R; Sabatucci I; Giorgi Rossi P
Int J Cancer; 2014 Feb; 134(4):897-904. PubMed ID: 23913416
[TBL] [Abstract][Full Text] [Related]
14. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
15. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial.
Cotton S; Sharp L; Little J; Cruickshank M; Seth R; Smart L; Duncan I; Harrild K; Neal K; Waugh N;
BJOG; 2010 May; 117(6):645-59. PubMed ID: 20374607
[TBL] [Abstract][Full Text] [Related]
16. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
[TBL] [Abstract][Full Text] [Related]
17. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.
Kyrgiou M; Kalliala IE; Mitra A; Fotopoulou C; Ghaem-Maghami S; Martin-Hirsch PP; Cruickshank M; Arbyn M; Paraskevaidis E
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD009836. PubMed ID: 28125861
[TBL] [Abstract][Full Text] [Related]
18. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
19. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
20. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
